Rochelle, Virginia (May 17, 2017) – NDA Partners Chairman Carl Peck, MD, announced today that Richard Kenley, PhD, senior business
executive and former CEO of Eurofins Advantar Laboratories and President of Pharmaceutical Development Business Unit of Cardinal Health,
has joined the firm as an Expert Consultant. In addition to his position at Eurofins and Cardinal Health, he was former Chief Operating
Officer at Anaborex, Senior VP and General Manager of the San Diego Facility of Magellan (acquired by Cardinal Health), and Founder and
General Manager of Cabrillo Laboratories (acquired by Magellan). Dr. Kenley is a recognized industry leader with experience in R&D, start-up
and in multinational corporate environments with expertise in small molecule and protein therapeutics, drug delivery systems and manufacturing.

“Dr. Kenley’s extensive experience in the start-up and multinational corporate environments, in addition to his expertise in small molecule
and protein therapeutics, drug delivery system development and manufacturing will provide an excellent resource to our clients,” said Dr. David
Savello, Partner and Manager, Product Quality & CMC Practice. “We are very pleased to welcome him to NDA Partners.”

Dr. Kenley earned his PhD in Chemistry from the University of California, San Diego and his BSc in Chemistry from the University of Illinois
Urbana-Champaign. He is a Fellow of the American Academy of Pharmaceutical Scientists, has four patents, and more than 60 peer-reviewed research
publications.

About NDA Partners
NDA Partners is a strategy consulting firm specializing in expert product development and regulatory advice to the medical products industry and associated service
industries such as law firms, investment funds and government research agencies. The highly experienced Principals and Premier Experts of NDA Partners include three
former FDA Center Directors; the former Chairman of the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK; an international team of more than 100
former pharmaceutical industry and regulatory agency senior executives; and an extensive roster of highly proficient experts in specialized areas including nonclinical
development, toxicology, pharmacokinetics, CMC, medical device design control and quality systems, clinical development, regulatory submissions, and development program
management. Services include product development and regulatory strategy, expert consulting, high-impact project teams, and virtual product development teams.